Quantum Biopharma Ltd. 6-K Filing
Ticker: QNTM · Form: 6-K · Filed: Dec 22, 2025 · CIK: 1771885
| Field | Detail |
|---|---|
| Company | Quantum Biopharma Ltd. (QNTM) |
| Form Type | 6-K |
| Filed Date | Dec 22, 2025 |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 6-K filing submitted by Quantum Biopharma Ltd. (ticker: QNTM) to the SEC on Dec 22, 2025.
How long is this filing?
Quantum Biopharma Ltd.'s 6-K filing is 1 pages with approximately 345 words. Estimated reading time is 1 minutes.
Where can I view the full 6-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 345 words · 1 min read · ~1 pages · Grade level 10.5 · Accepted 2025-12-22 16:23:02
Filing Documents
- g085049_6k.htm (6-K) — 16KB
- g085049_ex5-1.htm (EX-5.1) — 43KB
- g085049_ex10-1.htm (EX-10.1) — 242KB
- g085049_ex99-1.htm (EX-99.1) — 16KB
- img002_v1.jpg (GRAPHIC) — 8KB
- img001_v1.jpg (GRAPHIC) — 5KB
- 0001753926-25-001939.txt ( ) — 337KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Quantum BioPharma Ltd. (Registrant) Date: December 22, 2025 /s/ Donal Carroll Donal Carroll Chief Financial Officer EXHIBIT INDEX Exhibit Description of Exhibit 5.1 Opinion of Garfinkle Biderman LLP 10.1 At The Market Offering Agreement dated December 22, 2025 between Quantum BioPharma Ltd. (formerly FSD Pharma Inc.) and Rodman and Renshaw LLC 23.1 Consent of Garfinkle Biderman LLP (included in Exhibit 5.1) 99.1 Press Release – December 22, 2025 - Quantum BioPharma Ltd. Announces US ATM Offering